Literature DB >> 11276136

Effect of choice of reference equation on analysis of pulmonary function in cystic fibrosis patients.

M Rosenfeld1, M S Pepe, G Longton, J Emerson, S FitzSimmons, W Morgan.   

Abstract

Pulmonary function is an important measure of disease severity and prognosis in cystic fibrosis (CF). It is generally expressed as a percentage of a predicted value, calculated using regression equations derived from a reference population. A number of reference equations are in widespread use. The purposes of this study were to determine: 1) the extent to which, for a given absolute FEV(1) value, percent of predicted (PPFEV(1)) values vary when derived by different reference equations; and 2) whether these differences affect conclusions of longitudinal and cross-sectional analyses. Subjects were all Caucasians 6-18 years old in the 1990 Cystic Fibrosis Foundation Registry. We found clinically important discrepancies in PPFEV(1) when calculated by the methods of Dockery et al. [Am Rev Respir Dis 1983;128:405-412] and Wang et al. [Pediatr Pulmonol 1993;15:75-78] as compared to Knudson et al. [Am Rev Respir Dis 1983;127:725-734] or Polgar and Promadhat [Pulmonary Function Testing in Children 1971; Philadelphia: W.B. Saunders]. In longitudinal analyses, the choice of reference equation resulted in varying apparent rates of decline in FEV(1). For example, among subjects ages 12-14 years in 1990, the decline in PPFEV(1) from 1990-1995 varied between 2-11%, depending on the choice of reference equation. In cross-sectional analyses, the choice of reference equation affected the distribution of subjects classified as having mild, moderate, or severe lung disease. CF physicians should be aware of the impact of choice of reference equation in both clinical care and research. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2001        PMID: 11276136     DOI: 10.1002/ppul.1033

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  9 in total

1.  Heritability of lung disease severity in cystic fibrosis.

Authors:  Lori L Vanscoy; Scott M Blackman; Joseph M Collaco; Amanda Bowers; Teresa Lai; Kathleen Naughton; Marilyn Algire; Rita McWilliams; Suzanne Beck; Julie Hoover-Fong; Ada Hamosh; Dave Cutler; Garry R Cutting
Journal:  Am J Respir Crit Care Med       Date:  2007-03-01       Impact factor: 21.405

2.  Longitudinal pulmonary function of childhood bronchiectasis and comparison with cystic fibrosis.

Authors:  J Twiss; A W Stewart; C A Byrnes
Journal:  Thorax       Date:  2006-02-07       Impact factor: 9.139

3.  Effect of changing reference equations for spirometry interpretation in Thai people.

Authors:  Warawut Chaiwong; Sureeporn Uthaikhup; Chalerm Liwsrisakun; Chaicharn Pothirat
Journal:  J Thorac Dis       Date:  2019-01       Impact factor: 2.895

4.  Outcome measures for clinical trials assessing treatment of cystic fibrosis lung disease.

Authors:  Donald R VanDevanter; Michael W Konstan
Journal:  Clin Investig (Lond)       Date:  2012

Review 5.  The Global Lung Function Initiative (GLI) Network: bringing the world's respiratory reference values together.

Authors:  Brendan G Cooper; Janet Stocks; Graham L Hall; Bruce Culver; Irene Steenbruggen; Kim W Carter; Bruce Robert Thompson; Brian L Graham; Martin R Miller; Gregg Ruppel; John Henderson; Carlos A Vaz Fragoso; Sanja Stanojevic
Journal:  Breathe (Sheff)       Date:  2017-09

6.  Effect of change of reference standard to NHANES III on interpretation of spirometric 'abnormality'.

Authors:  Akshay Sood; Beth K Dawson; Joseph Q Henkle; Patricia Hopkins-Price; Clifford Quails
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2007

7.  Recommendations for using standardised phenotypes in genetic association studies.

Authors:  Melissa G Naylor; Scott T Weiss; Christoph Lange
Journal:  Hum Genomics       Date:  2009-07       Impact factor: 4.639

8.  Using different methods to process forced expiratory volume in one second (FEV 1) data can impact on the interpretation of FEV 1 as an outcome measure to understand the performance of an adult cystic fibrosis centre: A retrospective chart review.

Authors:  Zhe Hui Hoo; Muhaned S A El-Gheryani; Rachael Curley; Martin J Wildman
Journal:  F1000Res       Date:  2018-06-01

9.  Lung immunoglobulin A immunity dysregulation in cystic fibrosis.

Authors:  Amandine M Collin; Marylène Lecocq; Sabrina Noel; Bruno Detry; François M Carlier; Frank Aboubakar Nana; Caroline Bouzin; Teresinha Leal; Marjorie Vermeersch; Virginia De Rose; Lucile Regard; Clémence Martin; Pierre-Régis Burgel; Delphine Hoton; Stijn Verleden; Antoine Froidure; Charles Pilette; Sophie Gohy
Journal:  EBioMedicine       Date:  2020-09-11       Impact factor: 8.143

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.